AEterna Zentaris (t.aez, aezs) was expecting to have results of its phase 3 clinical trial for colon cancer in Q1 2012. Well as of today, Mar.21, there are only 10 days left in Q1 now. As the trial ends at 360 deaths, it could well mean that their cancer drug Perifosine is working very well. Good results here will have this stock flying as the phase 3 trial is the last one before an NDA (new drug application) can be applied to the FDA. This drug has blockbuster written all over it in my opinion as it is being tested along side a current blockbuster drug Xeloda that has projected sales of $3 billion annually. Thats $3,000,000,000 annually! The company also has a very deep pipeline of other potential blockbuster drugs in development. But the key thing here is results are due and good results should send this stock flying!